Literature DB >> 15786555

Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival.

Geng-Wen Huang1, Lian-Yue Yang, Wei-Qun Lu.   

Abstract

AIM: To study the expression of hypoxia-inducible factor 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) and the impact on neovascularization and survival.
METHODS: Expressions of HIF-1alpha, VEGF and microvessel density (MVD) are studied through immunohistochemistry in 36 cases of HCC and the corresponding paraneoplastic tissue and 6 cases of normal liver tissue. The relationship of the expressions of HIF-1alpha and VEGF with the clinicopathological data and survival are analyzed.
RESULTS: The positive rate of VEGF in HCC was 32/36, which is significantly higher than that in paraneoplastic tissue and normal liver tissue (P<0.05). The expression of HIF-1alpha in HCC tissue is 24/36, also higher than that in paraneoplastic tissue and normal liver tissue (P<0.05). The expression of VEGF and HIF-1alpha in HCC with microscopic venous invasion is significantly higher than that in HCC without microscopic venous invasion (P<0.05). Spearman correlation analysis does not only show the expression of HIF-1alpha as correlated with the expression of VEGF (r(s) = 0.459, P<0.01), but it also shows the expression of HIF-1alpha and VEGF as correlated with MVD (r(s) = 0.412 and 0.336, respectively, P<0.05). The differences of the survival rates among VEGF positive group and VEGF negative group are significant (P<0.05), whereas the differences of the survival rates among the HIF-1alpha negative group and positive group are not significant (P>0.05).
CONCLUSION: HIF-1alpha plays important roles in neovascularization in HCC possibly through regulation of VEGF transcription.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15786555      PMCID: PMC4305959          DOI: 10.3748/wjg.v11.i11.1705

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis.

Authors:  P Birner; B Gatterbauer; G Oberhuber; M Schindl; K Rössler; A Prodinger; H Budka; J A Hainfellner
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

3.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.

Authors:  B H Jiang; F Agani; A Passaniti; G L Semenza
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

4.  Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.

Authors:  K Shirabe; M Shimada; T Gion; H Hasegawa; K Takenaka; T Utsunomiya; K Sugimachi
Journal:  J Am Coll Surg       Date:  1999-03       Impact factor: 6.113

5.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

7.  Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia.

Authors:  A P Levy; N S Levy; S Wegner; M A Goldberg
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

Review 8.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.

Authors:  N Weidner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine.

Authors:  G Melillo; L S Taylor; A Brooks; T Musso; G W Cox; L Varesio
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

10.  Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  61 in total

Review 1.  Targeting the tumor stroma in hepatocellular carcinoma.

Authors:  Femke Heindryckx; Pär Gerwins
Journal:  World J Hepatol       Date:  2015-02-27

2.  EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway.

Authors:  Ruyue Ji; Chih-Ling Chou; Wei Xu; Xiao-Bo Chen; David F Woodward; John W Regan
Journal:  Mol Pharmacol       Date:  2010-03-24       Impact factor: 4.436

Review 3.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

4.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

Review 5.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

Review 6.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma.

Authors:  Erdenebulgan Batmunkh; Mitsuo Shimada; Yuji Morine; Satoru Imura; Hirofumi Kanemura; Yusuke Arakawa; Jun Hanaoka; Mami Kanamoto; Koji Sugimoto; Masaaki Nishi
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

Review 8.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis.

Authors:  Ivan Chebib; Meer Taher Shabani-Rad; Michelle S Chow; James Zhang; Zu-Hua Gao
Journal:  Biomark Insights       Date:  2007-02-14

10.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.